In the classical form of ?1antitrypsin deficiency (ATD) a point mutation leads to misfolding of a hepatic secretory protein and the variant, ?1antitrypsin Z (ATZ), accumulates in the ER of liver cells as polymers and aggregates. Liver fibrosis and hepatocellular carcinoma develops in a subgroup of affected homozygotes by a gain-of-function 'proteotoxic'mechanism. There is wide variability in the hepatic phenotype with ~10% affected in infancy/early childhood and another subgroup that develop liver disease in the 6th-7th decade of life by an apparent age-dependent process. The central hypothesis of our research has 3 components: 1) variability in hepatic phenotype is determined by genetic and environmental modifiers;2) the targets of these modifiers are the quality control mechanisms of the ER, part of the cell's proteostasis regulatory network;3) the 2 major types of protestasis mechanisms are protein degradation pathways, such as the proteasome and autophagy, and signaling pathways that are designed to protect cells from proteotoxicity. In this grant we propose investigation of the role of 3 signaling pathways that are putative proteostasis regulatory mechanisms designed to prevent liver damage, including the insulin and NF?B signaling pathways as well as the regulator of G signaling 16 (RGS16). The proposal is based on preliminary results showing that these 3 pathways are activated in unique ways in several model systems including mammalian cell line and mouse models with inducible expression of ATZ and a novel C. elegans model that facilitates mechanistic interrogation through rapid genetic engineering and drug discovery. We will determine how these pathways are activated and how they affect the hepatic phenotype of ATD by utilizing novel mouse models with targeted disruption of each pathway as well as by pharmacological strategies that influence the pathways. We will also determine whether there is variation in activation of these pathways among individual patients with ATD using iPS-derived hepatocyte cell lines.
These studies are designed to advance our understanding of the factors that lead to more severe liver disease in AT deficiency and the potential to target these factors for novel therapeutic strategies.
|Perlmutter, David H (2016) Current and Emerging Treatments for Alpha-1 Antitrypsin Deficiency. Gastroenterol Hepatol (N Y) 12:446-8|
|Chu, Andrew S; Chopra, Kapil B; Perlmutter, David H (2016) Is severe progressive liver disease caused by alpha-1-antitrypsin deficiency more common in children or adults? Liver Transpl 22:886-94|
|Tafaleng, Edgar N; Chakraborty, Souvik; Han, Bing et al. (2015) Induced pluripotent stem cells model personalized variations in liver disease resulting from Î±1-antitrypsin deficiency. Hepatology 62:147-57|
|Ghouse, Raafe; Chu, Andrew; Wang, Yan et al. (2014) Mysteries of Î±1-antitrypsin deficiency: emerging therapeutic strategies for a challenging disease. Dis Model Mech 7:411-9|
|Wang, Yan; Perlmutter, David H (2014) Targeting intracellular degradation pathways for treatment of liver disease caused by *1-antitrypsin deficiency. Pediatr Res 75:133-9|
|Long, Olivia S; Benson, Joshua A; Kwak, Joon Hyeok et al. (2014) A C. elegans model of human Î±1-antitrypsin deficiency links components of the RNAi pathway to misfolded protein turnover. Hum Mol Genet 23:5109-22|
|Chu, Andrew S; Perlmutter, David H; Wang, Yan (2014) Capitalizing on the autophagic response for treatment of liver disease caused by alpha-1-antitrypsin deficiency and other genetic diseases. Biomed Res Int 2014:459823|